Serina Therapeutics is a clinical-stage biotech company based in Huntsville, Alabama, focused on developing therapies for neurological diseases using its proprietary POZ (poly 2-oxazoline) polymer technology. This platform improves drug delivery and safety for small molecules, RNA therapies, and biologics. Serina merged with AgeX Therapeutics in 2024 and now trades on NYSE American as "SER." Its pipeline includes SER-252 for Parkinson’s, SER-227 for pain, and SER-228 for epilepsy. The company is also exploring RNA vaccine delivery. As of March 2025, it reported $142,000 in revenue and a $14.8 million net loss, with a team of just nine employees.